Top

The European Journal of Health Economics

Published in:

01-08-2011 | Original Paper

The impact of disease severity on EQ-5D and SF-6D utility discrepancies in chronic heart failure

Authors: Nick Kontodimopoulos, Michalis Argiriou, Nikolaos Theakos, Dimitris Niakas

Published in: The European Journal of Health Economics | Issue 4/2011

Abstract

Objectives

To compare EQ-5D and SF-6D utilities across groups of chronic heart failure (CHF) patients with varying levels of disease severity.

Methods

A consecutive sample (N = 251) of CHF patients undergoing elective cardiac surgery were surveyed. Disease severity was proxied via a self-assessment scale, the EQ-VAS and the Duke Activity Status Index (DASI); however, validity was demonstrated only by the latter. Association and level of agreement between instruments in DASI-based severity groups were estimated with Pearson’s r and the intraclass correlation coefficient (ICC), respectively. Paired-samples t test was used to identify significant differences. In a linear regression model, the DASI was used as an anchor of disease severity to identify a potential “crossover” point between EQ-5D and SF-6D utilities.

Results

EQ-5D and SF-6D strongly correlated over the entire sample (r = 0.647, P < 0.001); however, their agreement was moderate (ICC = 0.484, P < 0.001). In the less severe DASI groups (i.e. higher functional capacity) EQ-5D was significantly higher than SF-6D (P < 0.001) and differences constituted minimally important differences (MIDs). Contrarily, in the more severe groups SF-6D was predominantly higher than EQ-5D. The regression model indicated a utility crossover point at 0.722 and predicted that individuals with a utility score less than this would score higher on the SF-6D than on the EQ-5D, and vice versa. The DASI score at crossover was calculated at 31.94.

Conclusions

In subgroups of patients differing in CHF severity according to the DASI, mean EQ-5D and SF-6D indices differed significantly. Contrarily, in socio-demographic and clinical groups, these utility differences were not directly evident. According to the evidence, comparisons based on severity classification via a valid disease-specific external instrument may provide insight on instrument choice in cost-utility analyses.

McMurray, J.J., Pfeffer, M.A.: Heart failure. Lancet 365, 1877–1889 (2005)PubMedCrossRef

Stewart, S., Jenkins, A., Buchan, S., McGuire, A., Capewell, S., McMurray, J.J.: The current cost of heart failure to the National Health Service in the UK. Eur. J. Heart Fail. 4, 361–371 (2002)PubMedCrossRef

Rosamond, W., Flegal, K., Furie, K., Go, A., Greenlund, K., Haase, N., et al.: Heart disease and stroke statistics-2008 update: a report from the American heart association statistics committee and stroke statistics subcommittee. Circulation 117, e25–e146 (2008)PubMedCrossRef

Rich, M.W., Nease, R.F.: Cost-effectiveness analysis in clinical practice: the case of heart failure. Arch. Intern. Med. 159, 1690–1700 (1999)PubMedCrossRef

Juenger, J., Schellberg, D., Kraemer, S., Haunstetter, A., Zugck, C., Herzog, W., et al.: Health related quality of life in patients with congestive heart failure: comparison with other chronic diseases and relation to functional variables. Heart 87, 235–241 (2002)PubMedCrossRef

Hobbs, F.D., Kenkre, J.E., Roalfe, A.K., Davis, R.C., Hare, R., Davies, M.K.: Impact of heart failure and left ventricular systolic dysfunction on quality of life: a cross-sectional study comparing common chronic cardiac and medical disorders and a representative adult population. Eur. Heart J. 23, 1867–1876 (2002)PubMedCrossRef

Neubauer, S.: The failing heart—an engine out of fuel. N. Engl. J. Med. 356, 1140–1151 (2007)PubMedCrossRef

Weintraub, W.S., Cole, J., Tooley, J.F.: Cost and cost-effectiveness studies in heart failure research. Am. Heart J. 143, 565–576 (2002)PubMedCrossRef

Rasanen, P., Roine, E., Sintonen, H., Semberg-Konttinen, V., Ryynanen, O.P., Roine, R.: Use of quality-adjusted life years for the estimation of effectiveness of health care: a systematic literature review. Int. J. Tech. Assess Health Care 22, 235–241 (2006)CrossRef

10.

Bryan, S., Longworth, L.: Measuring health-related utility: why the disparity between EQ-5D and SF-6D? Eur. J. Health Econ. 6, 253–260 (2005)PubMedCrossRef

11.

Bleichrodt, H.: A new explanation for the difference between time trade-off utilities and standard gamble utilities. Health Econ. 11, 447–456 (2002)PubMedCrossRef

12.

Green, C., Brazier, J., Deverill, M.: Valuing health-related quality of life. A review of health state valuation techniques. Pharmacoeconomics 17, 151–165 (2000)PubMedCrossRef

13.

Dolan, P., Gudex, C., Kind, P., Williams, A.: Valuing health states: a comparison of methods. J. Health Econ. 15, 209–231 (1996)PubMedCrossRef

14.

Longworth, L., Bryan, S.: An empirical comparison of EQ-5D and SF-6D in liver transplant patients. Health Econ. 12, 1061–1067 (2003)PubMedCrossRef

15.

Gerard, K., Nicholson, T., Mullee, M., Mehta, R., Roderick, P.: EQ-5D versus SF-6D in an older, chronically ill patient group. Appl. Health Econ. Health Policy 3, 91–102 (2004)PubMedCrossRef

16.

Lamers, L.M., Bouwmans, C.A., van Straten, A., Donker, M.C., Hakkaart, L.: Comparison of EQ-5D and SF-6D utilities in mental health patients. Health Econ. 15, 1229–1236 (2006)PubMedCrossRef

17.

Xie, F., Li, S.C., Luo, N., Lo, N.N., Yeo, S.J., Yang, K.Y., et al.: Comparison of the EuroQol and short form 6D in Singapore multiethnic Asian knee osteoarthritis patients scheduled for total knee replacement. Arthritis Rheum. 57, 1043–1049 (2007)PubMedCrossRef

18.

van Stel, H.F., Buskens, E.: Comparison of the SF-6D and the EQ-5D in patients with coronary heart disease. Health Qual. Life Outcomes 4, 20 (2006)PubMedCrossRef

19.

Grieve, R., Grishchenko, M., Cairns, J.: SF-6D versus EQ-5D: reasons for differences in utility scores and impact on reported cost-utility. Eur. J. Health Econ. 10, 15–23 (2004)CrossRef

20.

Brazier, J., Roberts, J., Tsuchiya, A., Busschbach, J.: A comparison of the EQ-5D and SF-6D across seven patient groups. Health Econ. 13, 873–884 (2004)PubMedCrossRef

21.

Kontodimopoulos, N., Pappa, E., Papadopoulos, A.A., Tountas, Y., Niakas, D.: Comparing SF-6D and EQ-5D utilities across groups differing in health status. Qual. Life Res. 18, 87–97 (2009)PubMedCrossRef

22.

Barton, G.R., Sach, T.H., Avery, A.J., Doherty, M., Jenkinson, C., Muir, K.R.: Comparing the performance of the EQ-5D and SF-6D when measuring the benefits of alleviating knee pain. Cost Eff. Resour. Alloc. 7, 12 (2009)PubMedCrossRef

23.

Petrou, S., Hockley, C.: An investigation into the empirical validity of the EQ-5D and SF-6D based on hypothetical preferences in a general population. Health Econ. 14, 1169–1189 (2005)PubMedCrossRef

24.

Bharmal, M., Thomas 3rd, J.: Comparing the EQ-5D and the SF-6D descriptive systems to assess their ceiling effects in the US general population. Value Health 9, 262–271 (2006)PubMedCrossRef

25.

Barton, G.R., Sach, T.H., Avery, A.J., Jenkinson, C., Doherty, M., Whynes, D.K., et al.: A comparison of the performance of the EQ-5D and SF-6D for individuals aged > or = 45 years. Health Econ. 17, 815–832 (2008)PubMedCrossRef

26.

Tsevat, J., Duke, D., Goldman, L., Pfeffer, M.A., Lamas, G.A., Soukup, J.R., et al.: Cost-effectiveness of captopril therapy after myocardial infarction. J. Am. Coll. Cardiol. 26, 914–919 (1995)PubMedCrossRef

27.

Glick, H., Cook, J., Kinosian, B., Pitt, B., Bourassa, M.G., Pouleur, H., et al.: Costs and effects of enalapril therapy in patients with symptomatic heart failure: an economic analysis of the studies of left ventricular dysfunction (SOLVD) treatment trial. J. Card. Fail. 1, 371–380 (1995)PubMedCrossRef

28.

National Institute for Clinical Excellence: Guide to the methods of technology appraisal. NICE, London (2004)

29.

The EuroQol group: EuroQol—a new facility for the measurement of health related quality of life. Health Policy 16, 199–208 (1990)CrossRef

30.

Brooks, R.: EuroQol: the current state of play. Health Policy 37, 53–72 (1996)PubMedCrossRef

31.

Dolan, P.: Modeling valuations for EuroQol health states. Med. Care 35, 1095–1108 (1997)PubMedCrossRef

32.

Dolan, P., Gudex, C., Kind, P., Williams, A.: The time trade-off method: results from a general population study. Health Econ. 5, 141–154 (1996)PubMedCrossRef

33.

Yfantopoulos, J.: The Greek version of the EuroQol (EQ-5D) instrument. Arch. Hell. Med. 18, 180–191 (2001)

34.

Kontodimopoulos, N., Pappa, E., Niakas, D., Yfantopoulos, J., Dimitrakaki, C., Tountas, Y.: Validity of the EQ-5D instrument in a Greek general population. Value Health 11, 1162–1169 (2008)PubMedCrossRef

35.

Brazier, J., Roberts, J., Deverill, M.: The estimation of a preference-based measure of health from the SF-36. J. Health Econ. 21, 271–292 (2002)PubMedCrossRef

36.

Pappa, E., Kontodimopoulos, N., Niakas, D.: Validating and norming of the Greek SF-36 health survey. Qual. Life Res. 14, 1433–1438 (2005)PubMedCrossRef

37.

Anagnostopoulos, F., Niakas, D., Pappa, E.: Construct validation of the Greek SF-36 health survey. Qual. Life Res. 14, 1959–1965 (2005)PubMedCrossRef

38.

Kontodimopoulos, N., Niakas, D.: A cost-utility analysis in renal replacement therapy based on patients’ expected remaining life years. Health Policy 86, 85–96 (2008)PubMedCrossRef

39.

Hlatky, M.A., Boineau, R.E., Higginbotham, M.B., Lee, K.L., Mark, D.B., Califf, R.M., et al.: A brief self-administered questionnaire to determine functional capacity (The Duke activity status index). Am. J. Cardiol. 64, 651–654 (1989)PubMedCrossRef

40.

Mark, D.B., Naylor, C.D., Hlatky, M.A., Califf, R.M., Topol, E.J., Granger, C.B., et al.: Use of medical resources and quality of life after myocardial infarction in Canada and the United States. N. Engl. J. Med. 331, 1130–1135 (1994)PubMedCrossRef

41.

Pilote, L., Bourassa, M.G., Bacon, C., Bost, J., Detre, K., Mark, D.B., et al.: Better functional status in American than Canadian patients with heart disease: an effect of medical care? J. Am. Coll. Cardiol. 26, 1115–1120 (1995)PubMedCrossRef

42.

Roques, F., Nashef, S.A., Michel, P., Gauducheau, E., de Vincentiis, C., Baudet, E., et al.: Risk factors and outcome in European cardiac surgery: analysis of the Euro-SCORE multinational database of 19 030 patients. Eur. J. Cardiothorac. Surg. 15, 816–822 (1999)PubMedCrossRef

43.

Nashef, S.A., Roques, F., Michel, P., Gauducheau, E., Lemeshow, S., Salamon, R.: European system for cardiac operative risk evaluation (Euro-SCORE). Eur. J. Cardiothorac. Surg. 16, 9–13 (1999)PubMedCrossRef

44.

Cohen, J.: A power primer. Psychol. Bull. 112, 155–159 (1992)PubMedCrossRef

45.

Walters, S.J., Brazier, J.E.: What is the relationship between the minimally important difference and health state utility values? The case of the SF-6D. Health Qual. Life Outcomes 1, 4 (2003)PubMedCrossRef

46.

Sullivan, P.W., Lawrence, W.F., Ghushchyan, V.: A national catalog of preference-based scores for chronic conditions in the United States. Med. Care 43, 736–749 (2005)PubMedCrossRef

47.

Walters, S.J., Brazier, J.E.: Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D. Qual. Life Res. 14, 1523–1532 (2005)PubMedCrossRef

48.

Nelson, C.L., Herndon, J.E., Mark, D.B., Pryor, D.B., Califf, R.M., Hlatky, M.A.: Relation of clinical and angiographic factors to functional capacity as measured by the Duke activity status index. Am. J. Cardiol. 68, 973–975 (1991)PubMedCrossRef

49.

Parissis, J.T., Nikolaou, M., Birmpa, D., Farmakis, D., Paraskevaidis, I., Bistola, V., et al.: Clinical and prognostic value of Duke’s activity status index along with plasma B-type natriuretic peptide levels in chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am. J. Cardiol. 103, 73–75 (2009)PubMedCrossRef

Title: The impact of disease severity on EQ-5D and SF-6D utility discrepancies in chronic heart failure
Authors: Nick Kontodimopoulos
Michalis Argiriou
Nikolaos Theakos
Dimitris Niakas
Publication date: 01-08-2011
Publisher: Springer-Verlag
Published in: The European Journal of Health Economics / Issue 4/2011
Print ISSN: 1618-7598
Electronic ISSN: 1618-7601
DOI: https://doi.org/10.1007/s10198-010-0252-4

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The impact of disease severity on EQ-5D and SF-6D utility discrepancies in chronic heart failure

Abstract

Objectives

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objectives

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 4/2011

The costs of breast cancer prior to and following diagnosis

Incentives in primary care and their impact on potentially avoidable hospital admissions

Health burden and costs of obesity and overweight in Germany

Estimates of patient costs related with population morbidity: can indirect costs affect the results?

Resource use and costs of treating acute cough/lower respiratory tract infections in 13 European countries: results and challenges

What values do the public want their health care systems to use in evaluating technologies?